MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. :
MCE 国际站:c-Kit-IN-3 L-tartrate
产品活性:c-Kit-IN-3 L-tartrate (Compound 18) 是一种有效的 c-KIT 激酶抑制剂,对 c-KIT wt 和 c-KIT T670I 的 IC50 分别为 4 nM 和 8 nM。c-Kit-IN-3 L-tartrate 对近膜结构域中的大多数功能获得性突变,ATP 结合口袋中的抗药性突变以及激活环显示出强大的效力。
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:c-Kit
In Vitro: c-Kit-IN-3 L-tartrate (Compound 18; 0.1-10 μM; 6 days; primary GIST patient cells) exhibits dose-dependent antiproliferative effects.c-Kit-IN-3 L-tartrate (0.01-1 μM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment induces dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3).
c-Kit-IN-3 L-tartrate (0.01-1 μM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment arrests the cell cycle into the G0/G1 phase in all of these three cell lines.
c-Kit-IN-3 L-tartrate (0-1 μM; 24 hours) blocks the autophosphorylation of c-KIT pY703, pY719, and pY823 in GIST-T1, GIST-T1-T670I, and GIST-5R, respectively, cells at a concentration of 30 nM and inhibits the downstream signaling mediators pAKT (T308/S473), pS6 (S235/236), and pERK (T202/204).
c-Kit-IN-3 L-tartrate potently inhibits the activity of CSF1R (IC50: 18 nM), PDGFRα (IC50: 25 nM), RET (IC50: 34 nM), and it relatively less potently inhibits DDR1 (IC50: 135 nM), FLT4 (IC50: 121 nM), and PDGFRβ (IC50: 97 nM).
c-Kit-IN-3 L-tartrate (0.006 μM-1.37 μM) potently inhibits the growth of c-KIT-dependent GIST cancer cells, such as GIST-T1 (IC50: 0.006 μM); GIST-882 (IC50: 0.013 μM); GIST-T1-T670I (IC50: 0.011 μM); GIST-5R (IC50: 0.073 μM); GIST-48B (IC50: 1.37 μM), respectively.
In Vivo: c-Kit-IN-3 L-tartrate (Compound 18; oral gavage; 20-100 mg/kg/day; for 11 days; female BALB/C-nu mice) treatment dose dependently inhibits the tumor progression.
c-Kit-IN-3 L-tartrate (1 mg/kg (iv for mice, rats, dog); 10 mg/kg (p.o. for mice, rats ) and 5 mg/kg (p.o. for dog)) has T1/2 of 4.5 h, 6.4 h, 19.4 h for mice, rats and dogs, respectively. And it possesses acceptable bioavailability in mice (F = 43%), rats (F = 50%), and dogs (F = 81%).
相关产品:Pexidartinib | Lenvatinib | Imatinib | Cabozantinib | Pazopanib | Avapritinib | Ripretinib | Dovitinib | Masitinib | Sitravatinib | Linifanib | Flumatinib | Amuvatinib | Telatinib | Motesanib | Ki20227 | SU14813 | Tandutinib | AST 487 | ISCK03 | OSI-930 | Toceranib phosphate | AZD3229
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪前沿的制药及生命科学研究进展,为您提供全球前沿的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。